Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUG1ASO Phase Ib Trial in Recurrent Glioblastoma (TUG1b)
jRCT2051260110Phase 1Recruiting
- Start
- Jul 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of TUG1ASO in glioblastoma (GBM) (2 arms), sponsored by none. Primary endpoint: Safety and tolerability. Started Jul 2026; status: recruiting.
02
Drugs
TUG1ASO
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2051260110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260110.